The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and DesignHoward V.J.a · Cushman M.c · Pulley L.d · Gomez C.R.e · Go R.C.a · Prineas R.J.f · Graham A.g · Moy C.S.h · Howard G.b
Departments of aEpidemiology and bBiostatistics, University of Alabama at Birmingham, Birmingham, Ala., cDepartments of Medicine and Pathology, Laboratory for Clinical Biochemistry Research, University of Vermont, Burlington, Vt., dDepartment of Health Behavior, University of Arkansas Health Science University, Little Rock, Ark., eAlabama Neurological Institute, Birmingham, Ala., fDepartment of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, N.C., gExamination Management Services, Incorporated, Dallas, Tex., and hNational Institute of Neurological Disorders and Stroke, Rockville, Md., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study is a national, population-based, longitudinal study of 30,000 African-American and white adults aged ≧45 years. The objective is to determine the causes for the excess stroke mortality in the Southeastern US and among African-Americans. Participants are randomly sampled with recruitment by mail then telephone, where data on stroke risk factors, sociodemographic, lifestyle, and psychosocial characteristics are collected. Written informed consent, physical and physiological measures, and fasting samples are collected during a subsequent in-home visit. Participants are followed via telephone at 6-month intervals for identification of stroke events. The novel aspects of the REGARDS study allow for the creation of a national cohort to address geographic and ethnic differences in stroke.
© 2005 S. Karger AG, Basel
- Borhani NO: Changes and geographic distribution of mortality from cerebrovascular disease. Am J Public Health 1965;55:673–681.
- Lanska DJ: Geographic distribution of stroke mortality in the United States: 1939–1941 to 1979–1981. Neurology 1993;43:1839–1851.
- Casper ML, Wing S, Anda RF, Knowles M, Pollard RA: The shifting stroke belt. Changes in the geographic pattern of stroke mortality in the United States, 1962 to 1988. Stroke 1995;26:755–760.
- Howard G, Evans GW, Pearce K, Howard VJ, Bell RA, Mayer EJ, Burke GL: Is the stroke belt disappearing? An analysis of racial, temporal, and age effects. Stroke 1995;26:1153–1158.
- Perry HM, Roccella EJ: Conference Report on Stroke Mortality in the Southeastern United States. Hypertension 1998;31:1206–1215.
- Howard G, Anderson R, Johnson NJ, Sorlie P, Russell G, Howard VJ: Evaluation of social status as a contributing factor to the stroke belt region of the United States. Stroke 1997;28:936–940.
- Howard G: Why do we have a stroke belt in the southeastern United States? A review of unlikely and uninvestigated potential causes. Am J Med Sci 1999;317:160–167.
Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL: Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. Stroke 1994;25:2120–2125.
- Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R: The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998;29:415–421.
- Kannel WB: The Framingham Study: Its 50-year legacy and future promise. J Atheroscler Thromb 2000;6:60–66.
- Melton LJ III: History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266–274.
- Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–1994. Series 1: Programs and collection procedures. Vital Health Stat 1994;32:1–407.
- Gillum RF: Stroke mortality in blacks. Disturbing trends. Stroke 1999;30:1711–1715.
- Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO: Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373–380.
- Wolf PA, D’Agostino RB: Secular trends in stroke in the Framingham Study. Ann Epidemiol 1993;3:471–475.
- Kissela B, Schneider A, Kleindorfer D, Khoury J, Miller R, Alwell K, Woo D, Szaflarski J, Gebel J, Moomaw C, Pancioli A, Jauch E, Shukla R, Broderick J: Stroke in a biracial population: The excess burden of stroke among blacks. Stroke 2004;35:426–431.
- Schoenfeld DA: Sample-size formula for the proportional-hazards regression model. Biometrics 1983;39:499–503.
- The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687–702.
- Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, et al: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263–276.
- Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O’Leary D, Saad MF, Shea S, Szklo M, Tracy RP: Multi-ethnic study of atherosclerosis: Objectives and design. Am J Epidemiol 2002;156:871–881.
- Ware J Jr, Kosinski M, Keller SD: A 12-item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220–233.
- Berkman LF, Syme SL: Social networks, host resistance, and mortality: A nine-year follow-up study of Alameda County residents. Am J Epidemiol 1979;109:186–204.
- Jones WJ, Williams LS, Meschia JF: Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by neurological history and examination. Stroke 2001;32:2232–2236.
- Orme JG, Reis J, Herz EJ: Factorial and discriminant validity of the Center for Epidemiological Studies Depression (CES-D) scale. J Clin Psychol 1986;42:28–33.
- Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Soc Behav 1983;24:385–396.
- Callahan CM, Unverzagt FW, Hui SL, Perkins AJ, Hendrie HC: Six-item screener to identify cognitive impairment among potential subjects for clinical research. Med Care 2002;40:771–781.
- Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP: Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41:264–270.
- Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L: A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453–469.
- Rautaharju PM, Park LP, Chaitman BR, Rautaharju F, Zhang ZM: The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. J Electrocardiol 1998;31:157–187.
Prineas RJ, Blackburn H, Crow RS: The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston, Wright-PSG, 1982.
- The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 6 report. Arch Intern Med 1997;157:2413–2446.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;106:3143–3421.
- Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980–1985 World Health Organization diagnostic criteria. Diabetes Care 1997;20:1859–1862.
- Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM, Henkin L, Howard G, Savage PJ, Saad MF: The Insulin Resistance Atherosclerosis Study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 1995;5:464–472.
- Chambless LE, Toole JF, Nieto FJ, Rosamond W, Paton C: Association between symptoms reported in a population questionnaire and future ischemic stroke: The ARIC study. Neuroepidemiology 2004;23:33–37.
- Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF: Vitamin Intervention for Stroke Prevention (VISP) trial: Rationale and design. Neuroepidemiology 2001;20:16–25.
Lefkowitz DS, Brust JCM, Goldman L, Johnson JL, Toole JF, Howard V, Chambless L: A pilot study of the end point verification system in the Asymptomatic Carotid Atherosclerosis Study. J Stroke Cerebrovasc Dis 1992;2:92–99.
- Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III: Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
- Kasner SE, Cucchiara BL, McGarvey ML, Luciano JM, Liebeskind DS, Chalela JA: Modified National Institutes of Health Stroke Scale can be estimated from medical records. Stroke 2003;34:568–570.
- Elkind MS, Cheng J, Boden-Albala B, Paik MC, Sacco RL: Elevated white blood cell count and carotid plaque thickness: The Northern Manhattan Stroke Study. Stroke 2001;32:842–849.
- Cooper ES: Cardiovascular diseases and stroke in African Americans: A call for action. J National Med Ass 1993;85:97–100.
Census 2000 Summary File 1, Technical Documentation, Prepared by the U.S. Census Bureau, Washington, 2001.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.